This issue will bring you up to date on the impact of Psoriasis and recent developments in drug therapy.
• Psoriasis is recognized as an immunemediated, chronic, systemic inflammatory condition.
• About 80% of patients with mild to moderate psoriasis can be managed well with topical medications.
• Corticosteroids are the cornerstone of topical therapy.
Psoriasis is the most common autoimmune condition in the US, affecting 7.5 million people. It is a complex, genetically linked disease; 1 in every 3 patients with psoriasis has a relative with the condition. The human and economic tolls are significant. Patients with psoriasis have lower quality of life scores, along with increased occurrences of depression, anxiety and suicidal ideation. In the US, more than $63 million is spent annually in direct healthcare costs for psoriasis.
About The Author:
Celia P. MacDonnell, BS Pharmacy, PharmD is a Clinical Professor at the College of Pharmacy, University of Rhode Island. She is also an Adjunct Associate Professor of Family Medicine at the Alpert Medical School at Brown University. Her teaching, practice and research interests are in diseases of the eye and skin, and interprofessional education.